TL;DR
This study provides a comprehensive comparison of immune checkpoint inhibitor (ICI) combinations for extensive-stage small-cell lung cancer (ES-SCLC), revealing that while some regimens offer superior efficacy, none are cost-effective at the standard threshold in China. Tislelizumab plus chemotherapy emerges as the most cost-effective option when considering higher willingness-to-pay thresholds.
What Problem Does This Paper Address?
Small-cell lung cancer (SCLC), particularly in its extensive stage (ES-SCLC), is an aggressive disease with historically poor prognoses. While platinum-based chemotherapy has been the standard, its efficacy is limited. The advent of immune checkpoint inhibitors (ICIs) has revolutionized treatment, with combinations of ICIs and chemotherapy (sometimes with anti-angiogenic agents) showing improved outcomes. However, the landscape of these combination therapies is rapidly evolving, with numerous ICI options available. This creates a challenge for clinicians and healthcare systems: which combination offers the best balance of efficacy, safety, and cost-effectiveness, especially within the context of China's healthcare system? This paper aims to systematically address this by comparing all currently recommended ICI-based regimens for ES-SCLC.
Methods
The researchers employed two primary analytical techniques:
- Network Meta-Analysis (NMA): This statistical method was used to synthesize data from multiple randomized controlled trials (RCTs). Unlike traditional meta-analyses that compare only two treatments, NMA allows for indirect comparisons between treatments that haven't been directly compared in head-to-head trials. This was crucial for comparing the efficacy (overall survival - OS, progression-free survival - PFS, objective response rate - ORR) and safety (grade 3 adverse events - AEs) of eight different ICI-based regimens against each other and against chemotherapy alone. They used the Surface Under the Cumulative Ranking Area (SUCRA) to rank the treatments.
- Cost-Effectiveness Analysis (CEA): This economic evaluation was conducted from the perspective of the Chinese healthcare system. A 10-year partitioned survival model (PSM) was built to estimate total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). The model simulated patient transitions through three health states: progression-free survival (PFS), progressive disease (PD), and death. Costs included drug acquisition, AE management, and subsequent therapies. The willingness-to-pay (WTP) threshold was set at $40,500 per QALY, a standard benchmark in China.
Datasets
The study utilized data from eight Phase III randomized clinical trials (RCTs) published up to January 31, 2025. These trials were identified through a systematic search of major databases including PubMed, Web of Science, Cochrane Library, ClinicalTrials.gov, European Union Clinical Trials Register, and the Chinese Clinical Trial Registry. The specific trials included were CAPSTONE-1, KEYNOTE-604, ASTRUM-005, RATIONALE-312, IMpower133, CASPIAN, ETER701, and EXTENTORCH. Drug prices were sourced from a local database (pharnexcloud.com).
Key Insights and Ideas
- The ICI landscape is complex and rapidly evolving: The sheer number of ICI options and combinations necessitates systematic comparisons to guide clinical practice.
- Efficacy vs. Safety Trade-offs are significant: While some regimens show impressive efficacy gains, they may come with increased toxicity, highlighting the need for a balanced assessment.
- Cost is a major barrier to universal adoption: Even highly effective treatments may not be economically viable for widespread use, especially in resource-constrained healthcare systems.
- Willingness-to-pay is a critical factor: The "cost-effectiveness" of a treatment is not absolute but depends on the threshold set by the healthcare system, suggesting that treatments might become more attractive at higher WTP levels.
Key Results
- Efficacy Leaders: Benmelstobart plus anlotinib and chemotherapy demonstrated the strongest efficacy in improving OS, PFS, and ORR compared to chemotherapy alone. Serplulimab plus chemotherapy also showed significant benefits.
- Safety Profile: Tislelizumab plus chemotherapy exhibited the lowest incidence of grade 3 adverse events among the evaluated ICI-based regimens.
- Cost-Effectiveness:
- At the conventional WTP threshold of $40,500/QALY, none of the ICI-based regimens were found to be cost-effective compared to chemotherapy alone.
- Tislelizumab plus chemotherapy emerged as the most cost-effective option when considering higher WTP thresholds, offering a good balance of QALYs and costs. It achieved the second-highest QALYs (1.27) and second-lowest costs ($52,273.46) among the ICI regimens.
- Durvalumab plus chemotherapy was the least cost-effective, with the lowest QALYs and highest costs.
- Sensitivity Analyses: These analyses confirmed the robustness of the findings, indicating that drug costs and survival parameters (PFS) were key drivers of the ICERs.
Limitations and Future Work
The authors acknowledge several limitations:
- ICI Class Pooling: The NMA pooled PD-1 and PD-L1 inhibitors, which might obscure potential class-specific differences in efficacy or safety.
- AE Grading: Only grade ≥3 AEs were considered, potentially underestimating the impact of lower-grade toxicities on quality of life and thus overestimating cost-effectiveness. Disutility values for AEs were not incorporated.
- Data Extrapolation: While necessary for long-term projections, the use of published literature for health-state utilities and cost inputs introduces potential uncertainty.
- Uniformity Assumptions: Assumptions about subsequent therapies and AE management costs across all trials might not reflect real-world variations.
Future research should focus on identifying predictive biomarkers to personalize treatment, refining combination strategies to optimize efficacy while minimizing toxicity, and incorporating more granular quality-of-life data into cost-effectiveness models.
Summary updated